Genevieve A. Mortensen

Genevieve A. Mortensen

Auto-generated profile, based on publicly available information

Genevieve A. Mortensen

Indiana University Bloomington

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
NRNoor Radde
Noor Radde
GMGenevieve A. Mortensen
Genevieve A. Mortensen
DBDiya Bhat
Diya Bhat
SSShireen Shah
Shireen Shah
JCJoseph J. Clements
Joseph J. Clements
JBJeffrey E. Barrick
Jeffrey E. Barrick
Engineered DNA will slow the growth of a host cell if it redirects limiting resources or otherwise interferes with homeostasis. Escape mutants that alleviate this burden can rapidly evolve and take over cell populations, making genetic engineering less reliable and predictable. Synthetic biologists often use genetic parts encoded on plasmids, but their burden is rarely characterized. We measured how 301 BioBrick plasmids affected Escherichia coli growth and found that 59 (19.6%) were burdensome, primarily because they depleted the limited gene expression resources of host cells. Overall, no BioBricks reduced the growth rate of E. coli by >45%, which agreed with a population genetic model that predicts such plasmids should be unclonable. We made this model available online for education (https://barricklab.org/burden-model) and added our burden measurements to the iGEM Registry. Our results establish a fundamental limit on what DNA constructs and genetic modifications can be successfully engineered into cells.

5 May 2026 in Microbiology Spectrum
Verified
Journal Article
Open access
GMGenevieve A. Mortensen
Genevieve A. Mortensen
HSHaley Schmidt
Haley Schmidt
PRPredrag Radivojac
Predrag Radivojac
YYYuzhen Ye
Yuzhen Ye
DHDavid M. Haas
David M. Haas
The gut microbiome plays a vital role in maternal health and pregnancy outcomes, yet its impact on conditions like gestational hypertension (GH) and gestational diabetes mellitus (GDM) remains poorly understood. This study explores how the gut microbiome differs between pregnant women with these conditions and healthy controls, using metagenomic sequencing to analyze microbial composition and function. Our findings reveal that women with GH and GDM exhibit greater microbiome variability and distinct shifts in bacterial communities compared to healthy pregnancies. Key beneficial bacteria, such as Bacteroides fragilis and Roseburia intestinalis , were reduced in cases, suggesting potential disruptions in gut-related metabolic and immune functions. In addition to multiple differentially abundant species of Sphingobacterium in cases versus controls, functional analysis indicated changes in carbohydrate and lipid metabolism, reinforcing the microbiome’s connection to metabolic health. Furthermore, machine learning models demonstrated promising results in predicting disease status based on microbiome data, underscoring the potential for gut bacteria as potential predictive biomarkers for pregnancy-related conditions. These insights highlight the gut microbiome’s role in pregnancy health and suggest it may be a promising target for future interventions aimed at reducing complications and improving maternal-fetal outcomes. IMPORTANCE: Gut microbial dysbiosis has been implicated in pregnancy complications, yet most studies rely on 16S rRNA sequencing, which limits resolution and functional insight. Here, using shotgun metagenomic sequencing and machine learning, we identified robust microbial taxonomic and functional signatures that distinguish gestational hypertension and gestational diabetes from healthy pregnancies. A combined feature set enabled accurate classification of disease status, with overlapping features between statistical and predictive frameworks underscoring biological relevance. Altogether, our study defines high-resolution microbiome signatures with translational potential as predictive biomarkers for maternal health, while also providing an open, reproducible analysis pipeline to support future investigations.

7 August 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
YSYanhua Sun
Yanhua Sun
JLJiangqiong Li
Jiangqiong Li
XLXiang Liu
Xiang Liu
GMGenevieve A. Mortensen
Genevieve A. Mortensen
XGXiaoping Gu
Xiaoping Gu
LMLingzhong Meng
Lingzhong Meng
Haemodynamic management in critical care typically relies on static, population-based targets that overlook patient-specific physiology and the evolving nature of illness. We develop and validate a framework for real-time, personalised haemodynamic management using a time-dependent Cox model that integrates static and dynamic clinical data to predict survival probabilities and derive optimal heart rate and systolic blood pressure targets over time. Trained on the electronic Intensive Care Unit dataset and externally validated with Medical Information Mart for Intensive Care IV and Indiana University Health cohorts, the model demonstrates high predictive accuracy (c-index up to 0.931) and generalisability across diverse populations. Patients with heart rate and systolic blood pressure values closer to model-predicted targets exhibit significantly lower intensive care unit mortality than those aligned with fixed, population-based thresholds. Exploratory dose-response and propensity score–matched analyses confirm outcome relevance, while case studies illustrate feasibility in critical care settings. This personalised, dynamic approach—termed Haemodynamic Management by Time-Adaptive, Risk-Guided Estimation of Targets (HM-TARGET)—offers a scalable framework for precision haemodynamic management in critically ill patients. Prospective trials are warranted to evaluate clinical impact.

25 June 2026 in bioRxiv
Verified
Preprint
Open access
GMGenevieve A. Mortensen
Genevieve A. Mortensen
EMEmily E. Montgomery
Emily E. Montgomery
INInnocent Ng’OMbwa
Innocent Ng’OMbwa
SSShannon R. Smoot
Shannon R. Smoot
DSDaniel Stephenson
Daniel Stephenson
DCDaniella E. Chusyd
Daniella E. Chusyd
Aging is accompanied by widespread metabolic change, but it remains unclear which features are shared across species with different physiology, lifespan, and sampling contexts. To address this, we employed a pathway-centered comparative metabolomics framework to evaluate age-associated metabolic remodeling across wild African savanna elephant, mouse, and Drosophila melanogaster. Drosophila provided a controlled adult time course to map age-associated metabolite trajectories, while mouse and elephant plasma datasets allowed us to test whether these pathway signatures extended to mammalian aging. Adult Drosophila showed extensive metabolomic remodeling, with significant metabolites organizing into distinct temporal trajectory classes. Cross-species aging-associated metabolic correspondence was more apparent at the pathway level than at the level of individual metabolites. Pathway scores derived from Drosophila increased progressively with fly age, successfully distinguished young and old mice, and captured age-associated stratification across the elephant lifespan. Notably, lipid metabolism, particularly carnitine and fatty acid metabolism, together with nucleotide-related pathways, consistently emerged as the core features of aging across analyses. These findings suggest pathway-level metabolic remodeling is a recurrent feature of cross-species aging.